Protocol Library
30 research-backed protocols across 11 peptides · 19 citations
BPC-157
Healing
Recovery250–500 mcg· Once daily · SubQ
Cycle: 4 wk on / 2 wk off
Often paired with TB-500 for synergistic soft-tissue recovery. Inject near the injured area when feasible; otherwise abdominal subQ.
Contraindications (3)
- Active malignancy (theoretical angiogenic concern)
- Pregnancy or breastfeeding (no safety data)
- Known peptide allergy
BPC-157
Healing
Injury Repair500–750 mcg· Twice daily · SubQ
Cycle: 6 wk on / 4 wk off
Acute injury protocol: split into AM/PM doses. Local subQ near the injury site is the most common research route; abdominal subQ is acceptable. Often stacked with TB-500 for tendon or ligament injury.
Contraindications (3)
- Active malignancy (theoretical angiogenic concern)
- Pregnancy or breastfeeding (no safety data)
- Pre-existing thrombotic disorder without physician oversight
BPC-157
Healing
Longevity200–300 mcg· Once daily · SubQ
Cycle: 8 wk on / 4 wk off
Low-dose maintenance for gut-axis and vascular support. Oral compounded forms are sometimes used for GI-targeted dosing but bioavailability is poorly characterized — subQ remains the best-studied route.
Contraindications (2)
- Active malignancy (theoretical angiogenic concern)
- Pregnancy or breastfeeding (no safety data)
TB-500
Healing
Recovery2000–5000 mcg· Twice weekly · SubQ
Cycle: 6 wk on / 4 wk off
Loading phase common (5 mg twice weekly for 4-6 weeks) then drop to 2-2.5 mg weekly maintenance. Frequently stacked with BPC-157 for soft-tissue recovery.
Contraindications (3)
- Active malignancy (actin-binding pro-migratory effects)
- Pregnancy or breastfeeding
- Known peptide allergy
TB-500
Healing
Injury Repair5000–7500 mcg· Twice weekly · SubQ
Cycle: 4 wk on / 4 wk off
Aggressive loading for acute tendon, ligament, or muscle injury. Drop to maintenance (2-2.5 mg/week) after the loading phase. BPC-157 is the most common stack partner.
Contraindications (3)
- Active malignancy (actin-binding pro-migratory effects)
- Pregnancy or breastfeeding
- Concurrent immunosuppression without oversight
TB-500
Healing
Longevity1000–2000 mcg· Once weekly · SubQ
Cycle: 8 wk on / 4 wk off
Low-dose maintenance for vascular and cardiac support. Long-term safety data in humans is limited; pulse rather than continuous use.
Contraindications (3)
- Active malignancy
- Pregnancy or breastfeeding
- Known peptide allergy
Ipamorelin
Growth Hormone
Recovery200–300 mcg· Three times daily · SubQ
Cycle: 12 wk on / 4 wk off
Pre-workout, post-workout, and pre-sleep dosing maximizes GH pulses. Commonly stacked with CJC-1295 (no DAC) for amplified amplitude. Inject on an empty stomach to avoid blunting GH release.
Contraindications (4)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Critical illness (GH axis caution)
- Diabetic retinopathy
Ipamorelin
Growth Hormone
Longevity100–200 mcg· Once daily before sleep · SubQ
Cycle: 12 wk on / 4 wk off
Pre-sleep dosing aligns with the largest endogenous GH pulse. Often blended with CJC-1295 (no DAC). Selective GHS so does not elevate cortisol or prolactin appreciably.
Contraindications (3)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Diabetic retinopathy
Ipamorelin
Growth Hormone
Sleep200–300 mcg· Once nightly · SubQ
Cycle: 8 wk on / 4 wk off
Inject 30-60 minutes before bed on an empty stomach. The GH pulse from a ghrelin receptor agonist can increase slow-wave sleep depth. Stack with CJC-1295 (no DAC) for amplified amplitude.
Contraindications (3)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Active acromegaly
Ipamorelin
Growth Hormone
Fat Loss200–300 mcg· Twice daily (AM fasted + pre-sleep) · SubQ
Cycle: 12 wk on / 4 wk off
Pair with caloric deficit and resistance training. AM dose taken fasted; pre-sleep dose 2+ hours after the last meal. Often stacked with CJC-1295 (no DAC) to amplify pulse amplitude.
Contraindications (3)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Type 2 diabetes without glucose monitoring
CJC-1295 (no DAC)
Growth Hormone
Recovery100–200 mcg· Once daily before sleep · SubQ
Cycle: 12 wk on / 4 wk off
CJC-1295 without DAC (Mod GRF 1-29) has a short half-life that preserves natural pulsatility. Most studied as a stack with Ipamorelin for amplified, physiological GH release.
Contraindications (4)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Diabetic retinopathy
- Active acromegaly
CJC-1295 (no DAC)
Growth Hormone
Longevity100–150 mcg· Once daily before sleep · SubQ
Cycle: 16 wk on / 4 wk off
Low-dose maintenance to gently elevate GH/IGF-1 while preserving pulsatility. Pair with Ipamorelin pre-sleep for the most studied longevity stack.
Contraindications (4)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Diabetic retinopathy
- Active acromegaly
CJC-1295 (no DAC)
Growth Hormone
Fat Loss100–200 mcg· Twice daily (AM fasted + pre-sleep) · SubQ
Cycle: 12 wk on / 4 wk off
Combine with caloric deficit and resistance training. Most users stack with Ipamorelin to amplify pulse amplitude. Without DAC variant only — DAC variant blunts pulsatility.
Contraindications (4)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Type 2 diabetes without glucose monitoring
- Active acromegaly
CJC-1295 with DAC
Growth Hormone
Longevity1000–2000 mcg· Twice weekly · SubQ
Cycle: 12 wk on / 4 wk off
The DAC (drug affinity complex) variant binds albumin and has an ~8 day half-life, producing a tonic GH elevation rather than pulses. Some practitioners prefer the no-DAC variant to preserve natural pulsatility; choose intentionally.
Contraindications (4)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Diabetic retinopathy
- Active acromegaly
Tesamorelin
Metabolic
Fat Loss1000–2000 mcg· Once daily · SubQ
Cycle: 26 wk on / 4 wk off
FDA-approved at 2 mg SubQ daily for HIV-associated lipodystrophy; visceral fat reduction is the most replicated effect. Abdominal subQ rotating sites. Monitor IGF-1 and fasting glucose every 3 months.
Contraindications (4)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Hypothalamic-pituitary axis disease
- Diabetic retinopathy
Tesamorelin
Metabolic
Longevity500–1000 mcg· Once daily before sleep · SubQ
Cycle: 16 wk on / 4 wk off
Lower-than-label dose explored in non-HIV populations for IGF-1 modulation and visceral fat. Monitor IGF-1 and fasting glucose. Tesamorelin is a stabilized GHRH analog with longer action than sermorelin.
Contraindications (4)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Hypothalamic-pituitary axis disease
- Diabetic retinopathy
Tesamorelin
Metabolic
Cognitive1000–2000 mcg· Once daily · SubQ
Cycle: 20 wk on / 8 wk off
Explored in healthy older adults and MCI populations; tesamorelin has demonstrated favorable cognitive signals in small trials secondary to GHRH-axis modulation. Monitor IGF-1 and fasting glucose.
Contraindications (4)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Hypothalamic-pituitary axis disease
- Diabetic retinopathy
Sermorelin
Growth Hormone
Longevity200–500 mcg· Once daily before sleep · SubQ
Cycle: 16 wk on / 4 wk off
GHRH(1-29) analog; preserves natural pulsatility because the GHRH receptor signal is short-lived. Inject pre-sleep on an empty stomach. Often paired with a GHRP (Ipamorelin) for amplified pulse amplitude.
Contraindications (4)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Hypothalamic-pituitary axis disease
- Severe untreated hypothyroidism
Sermorelin
Growth Hormone
Sleep200–300 mcg· Once nightly · SubQ
Cycle: 12 wk on / 4 wk off
GHRH analog dosing pre-sleep aligns with the largest endogenous GH pulse and can increase slow-wave sleep. Empty stomach for at least 2 hours prior.
Contraindications (3)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Hypothalamic-pituitary axis disease
Sermorelin
Growth Hormone
Recovery300–500 mcg· Once daily before sleep · SubQ
Cycle: 12 wk on / 4 wk off
Pre-sleep dosing for recovery-oriented GH/IGF-1 modulation. Stack with Ipamorelin for amplified pulse amplitude — both peptides have favorable selectivity profiles.
Contraindications (4)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Hypothalamic-pituitary axis disease
- Diabetic retinopathy
MK-677 (Ibutamoren)
Growth Hormone
Sleep10000–25000 mcg· Once daily before sleep · Oral
Cycle: 12 wk on / 4 wk off
Oral ghrelin mimetic with ~24h half-life; pre-sleep dosing favors slow-wave and REM sleep increases reported in trials. Expect appetite stimulation and possible water retention; monitor fasting glucose.
Contraindications (5)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Type 2 diabetes without glucose monitoring
- Congestive heart failure
- Diabetic retinopathy
MK-677 (Ibutamoren)
Growth Hormone
Recovery10000–25000 mcg· Once daily · Oral
Cycle: 12 wk on / 4 wk off
Oral dosing for trainee recovery. Sustained GH/IGF-1 elevation without injections. Side effects: appetite increase, mild fluid retention, occasional lethargy in early weeks. Cycle to avoid receptor desensitization.
Contraindications (4)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Type 2 diabetes without glucose monitoring
- Congestive heart failure
MK-677 (Ibutamoren)
Growth Hormone
Longevity10000–15000 mcg· Once daily · Oral
Cycle: 16 wk on / 8 wk off
Low-end dosing for sustained GH/IGF-1 lift in older adults. Nass et al. demonstrated 1.6 kg fat-free mass gain over 12 months in healthy older adults. Monitor fasting glucose and HbA1c quarterly.
Contraindications (5)
- Active or prior malignancy
- Pregnancy or breastfeeding
- Type 2 diabetes without glucose monitoring
- Congestive heart failure
- Diabetic retinopathy
GHK-Cu
Anti-aging
Longevity1000–3000 mcg· Three times weekly · SubQ
Cycle: 8 wk on / 4 wk off
Copper tripeptide with gene-modulating effects in human studies. Topical formulations are widely used cosmetically; subQ is the most-studied systemic route. Do not stack with high-dose zinc (competes with copper transport).
Contraindications (4)
- Wilson's disease or other copper-handling disorder
- Active malignancy (theoretical angiogenic concern)
- Pregnancy or breastfeeding
- Known peptide allergy
GHK-Cu
Anti-aging
Injury Repair2000–3000 mcg· Three times weekly · SubQ
Cycle: 6 wk on / 4 wk off
Local subQ near the injury site is common when accessible; abdominal subQ otherwise. Reconstitute with bacteriostatic water and protect from light — GHK-Cu is light-sensitive.
Contraindications (3)
- Wilson's disease or other copper-handling disorder
- Active malignancy
- Pregnancy or breastfeeding
GHK-Cu
Anti-aging
Recovery1000–2000 mcg· Twice weekly · SubQ
Cycle: 8 wk on / 4 wk off
Low-dose maintenance for skin and connective tissue support. Protect reconstituted vials from light; refrigerate. Avoid stacking with high-dose zinc supplementation.
Contraindications (3)
- Wilson's disease or other copper-handling disorder
- Active malignancy
- Pregnancy or breastfeeding
Selank
Cognitive
Cognitive250–500 mcg· Twice daily · Nasal
Cycle: 4 wk on / 2 wk off
Russian-developed anxiolytic with GABAergic modulation; intranasal delivery is the route of clinical study. Non-sedating, non-addictive in trials. Often considered for performance-related anxiety vs. clinical anxiety.
Contraindications (3)
- Pregnancy or breastfeeding
- Known peptide allergy
- Use in children without specialist oversight
Selank
Cognitive
Sleep250–500 mcg· Once nightly · Nasal
Cycle: 4 wk on / 2 wk off
Selank's anxiolytic action via GABAergic modulation can improve sleep onset in anxiety-driven insomnia. Intranasal route per clinical study. Short pulse cycles rather than continuous use.
Contraindications (2)
- Pregnancy or breastfeeding
- Known peptide allergy
DSIP
Cognitive
Sleep100–250 mcg· Once nightly · SubQ
Cycle: 4 wk on / 2 wk off
Delta Sleep-Inducing Peptide named for early reports of slow-wave sleep promotion. Modern evidence remains mixed — Kovalzon's 2006 review described DSIP as an 'unresolved riddle.' Short pulse cycles only; treat as exploratory.
Contraindications (3)
- Pregnancy or breastfeeding
- Known peptide allergy
- Use without medical supervision in chronic insomnia
DSIP
Cognitive
Recovery100–200 mcg· Once nightly · SubQ
Cycle: 4 wk on / 2 wk off
Recovery framing leans on the hypothesized slow-wave sleep effect rather than direct tissue evidence. Evidence is weak; pulse use only and prioritize confirmed-effective sleep peptides (e.g., GHRH/GHRP class) when appropriate.
Contraindications (2)
- Pregnancy or breastfeeding
- Known peptide allergy
For educational purposes only. Not medical advice.